Skip to content

INTELLIA THERAPEUTICS, INC.

NTLA

CIK 0001652130

← back to feed
Revenue (TTM)
$59.7M
+16.9% YoY Q1 Apr 2026
Net Income (TTM)
−$413.14M
+20.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.81
+27.4% YoY Q1 Apr 2026
Gross Margin
100.0%
Q1 Apr 2026
Operating Margin
-741.7%
Q1 Apr 2026
Net Margin
-692.0%
Q1 Apr 2026
Free Cash Flow (TTM)
−$503.42M
Q1 Apr 2026
Cash
$134.7M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
139.72M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings